Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia

MGS0274 besylate is an ester‐based lipophilic prodrug of a metabotropic glutamate (mGlu) 2 and mGlu3 receptor agonist MGS0008 and being developed for the treatment of schizophrenia. We investigated the disposition of these compounds in rats and monkeys and in vitro metabolism in humans to evaluate w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Kohnosuke, Ochi, Motoki, Iwata, Katsuya, Fukasawa, Misako, Yamaguchi, Jun‐ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743422/
https://www.ncbi.nlm.nih.gov/pubmed/31523433
http://dx.doi.org/10.1002/prp2.520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743422/
https://www.ncbi.nlm.nih.gov/pubmed/31523433
http://dx.doi.org/10.1002/prp2.520

Ejemplares similares